Global X Japan Co. Ltd. Increases Stock Position in AbbVie Inc. $ABBV

Key Points

• Global X Japan Co. Ltd. boosted its stake in AbbVie by 294.6% in Q4, acquiring an additional 75,595 shares to hold 101,259 shares worth about $23.14 million, making AbbVie its 17th-largest position (≈1.8% of holdings).
• AbbVie beat Q4 expectations with EPS of $2.71 versus $2.65 and revenue of $16.62 billion (up 10% YoY), and issued FY2026 guidance of 14.370–14.570 EPS and Q1 guidance of 2.970–3.010 EPS.
• The company declared a quarterly dividend of $1.73 per share (annualized $6.92, ~3.3% yield; ex-dividend April 15, payable May 15), while insiders sold material stakes (EVP Perry C. Siatis sold 22,381 shares; SVP David Ryan Purdue sold 5,230 shares).

Global X Japan Co. Ltd. boosted its holdings in AbbVie Inc. (NYSE:ABBV - Free Report) by 294.6% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 101,259 shares of the company's stock after acquiring an additional 75,595 shares during the quarter. AbbVie accounts for approximately 1.8% of Global X Japan Co. Ltd.'s holdings, making the stock its 17th largest position. Global X Japan Co. Ltd.'s holdings in AbbVie were worth $23,137,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Brighton Jones LLC lifted its stake in AbbVie by 17.4% during the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company's stock valued at $4,072,000 after acquiring an additional 3,401 shares during the period. Revolve Wealth Partners LLC grew its stake in shares of AbbVie by 72.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company's stock worth $1,294,000 after acquiring an additional 3,064 shares during the period. Schnieders Capital Management LLC. grew its stake in shares of AbbVie by 5.0% in the second quarter. Schnieders Capital Management LLC. now owns 16,466 shares of the company's stock worth $3,056,000 after acquiring an additional 789 shares during the period. Richmond Investment Services LLC purchased a new position in shares of AbbVie during the second quarter valued at approximately $283,000. Finally, Maia Wealth LLC raised its holdings in shares of AbbVie by 2.2% during the second quarter. Maia Wealth LLC now owns 3,113 shares of the company's stock valued at $578,000 after purchasing an additional 67 shares during the last quarter. Institutional investors own 70.23% of the company's stock.

AbbVie Trading Up 1.9%

Shares of ABBV stock opened at $211.12 on Friday. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The stock has a market cap of $373.29 billion, a P/E ratio of 89.46, a P/E/G ratio of 0.72 and a beta of 0.34. The company has a 50 day simple moving average of $222.06 and a two-hundred day simple moving average of $224.53.

AbbVie (NYSE:ABBV - Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping the consensus estimate of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The business had revenue of $16.62 billion for the quarter, compared to analysts' expectations of $16.39 billion. During the same quarter last year, the company posted $2.16 EPS. The company's revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. As a group, equities analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th will be issued a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 3.3%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's payout ratio is currently 293.22%.

Insider Transactions at AbbVie

In other news, SVP David Ryan Purdue sold 5,230 shares of AbbVie stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total transaction of $1,221,518.80. Following the transaction, the senior vice president directly owned 2,654 shares of the company's stock, valued at $619,868.24. The trade was a 66.34% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Perry C. Siatis sold 22,381 shares of the business's stock in a transaction that occurred on Wednesday, February 25th. The shares were sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company's stock, valued at approximately $8,771,510. This trade represents a 36.98% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 0.25% of the company's stock.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on ABBV. BMO Capital Markets restated an "outperform" rating on shares of AbbVie in a report on Monday, March 9th. HSBC upgraded shares of AbbVie from a "hold" rating to a "buy" rating and boosted their target price for the company from $225.00 to $265.00 in a research note on Wednesday, December 10th. Guggenheim reissued a "buy" rating on shares of AbbVie in a report on Thursday, March 12th. Sanford C. Bernstein restated a "market perform" rating on shares of AbbVie in a research note on Thursday, February 5th. Finally, Morgan Stanley lifted their price objective on AbbVie from $269.00 to $270.00 and gave the stock an "overweight" rating in a report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have given a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $253.15.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Allergan Aesthetics will present 21 evidence-based e-posters at AMWC 2026, highlighting clinical and real‑world data that support product leadership and could help maintain premium pricing and practitioner demand. Allergan Aesthetics Reinforces Scientific Differentiation and Leadership with 21 Evidence-Based E-Posters at the 2026 Aesthetic & Anti-Aging Medicine World Congress (AMWC)
• Positive Sentiment: Allergan is promoting a new “Undetectable” era for JUVÉDERM at AMWC, a marketing/product push that may support volume and pricing for AbbVie’s largest aesthetics franchise. Allergan Aesthetics Ushers in a New Age of Hyaluronic Acid (HA) Injectables with JUVÉDERM® at AMWC Monaco
• Positive Sentiment: Erste Group nudged up its FY2027 EPS forecast for AbbVie (to $16.16), a small analyst lift that signals growing analyst confidence in longer‑term earnings power. Erste Group Bank upped their FY2027 earnings per share (EPS) estimates for AbbVie
• Positive Sentiment: AbbVie’s official partnership with MLB (seasonal marketing/awareness) can broaden brand visibility for patient and provider audiences and is a supportive commercial catalyst. How AbbVie’s official partnership with MLB will unfold over the course of the season
• Neutral Sentiment: Zacks and other outlets note elevated investor attention on AbbVie and publish comparative takes (e.g., vs. Eli Lilly) — increased search/coverage can raise short-term volatility but also liquidity. Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
• Neutral Sentiment: Coverage labeling AbbVie as a candidate in the psychedelics/psychiatry theme (coverage of bretisilocin acquisition) may attract growth‑oriented investors, but clinical risk and long timelines keep impact uncertain. Is AbbVie (ABBV) one of the Best Psychedelic Stocks to Buy in 2026?
• Negative Sentiment: Analyst commentary and valuation pieces point to recent share weakness (declines over the past week/month) and ongoing valuation questions despite multi-year gains, which can cap near‑term upside. Is AbbVie (ABBV) Now Offering Value After Recent Share Price Weakness?

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.